Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Viralkumar Shah to Hypoglycemic Agents

This is a "connection" page, showing publications Viralkumar Shah has written about Hypoglycemic Agents.

 
Connection Strength
 
 
 
13.654
 
  1. Montaser E, Bhasin K, Kruger D, Akturk HK, Ahmann A, Snell-Bergeon JK, Shah VN. Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST-T1D Extension Study. Diabetes Obes Metab. 2026 Nov; 28(11):10736-10742.
    View in: PubMed
    Score: 0.485
  2. Ambalavanan J, Bhasin K, Shah VN. Clinical Guidance on the Safe Use of Sodium-Glucose Cotransporter Inhibitors in Adults with Type 1 Diabetes. Endocrinol Metab Clin North Am. 2026 Sep; 55(3):537-546.
    View in: PubMed
    Score: 0.475
  3. Saeed ZI, Shah VN. Clinical Guidance on the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in Adults with Type 1 Diabetes. Endocrinol Metab Clin North Am. 2026 Sep; 55(3):525-536.
    View in: PubMed
    Score: 0.475
  4. Karakus KE, Akturk HK, Kruger D, Ahmann A, Bharvaga A, Langel CR, Ackeifi CA, Rosen J, Pyle L, Snell-Bergeon JK, Shah VN. Effect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis. Diabetes Care. 2026 May 01; 49(5):718-723.
    View in: PubMed
    Score: 0.474
  5. Shah VN, Choudhary P, Halperin I, Rabbone I, Zaharieva DP, Messer L. Rethinking control-IQ+ technology: Simple strategies for easy optimization. Diabetes Obes Metab. 2026 05; 28(5):3502-3514.
    View in: PubMed
    Score: 0.465
  6. Saeed ZI, Ambalavanan J, Rayan MN, Patadia P, Shah VN. Noninsulin Therapies in Management of Type 1 Diabetes. Endocr Pract. 2025 Nov; 31(11):1509-1520.
    View in: PubMed
    Score: 0.447
  7. Shah VN, Akturk HK, Kruger D, Ahmann A, Bhargava A, Bakoyannis G, Pyle L, Snell-Bergeon JK. Semaglutide in Adults with Type 1 Diabetes and Obesity. NEJM Evid. 2025 Aug; 4(8):EVIDoa2500173.
    View in: PubMed
    Score: 0.446
  8. Carlson AL, Badlani S, Shah VN. The Role, Potential Benefits and Cost-effectiveness of Digital Tools for Diabetes Management. Clin Ther. 2025 Aug; 47(8):638-648.
    View in: PubMed
    Score: 0.445
  9. Scifres CM, Cleary EM, Sheerer M, Bowdler M, Shah VN. Navigating Automated Insulin Delivery for Type 1 Diabetes Management During Pregnancy. J Diabetes Sci Technol. 2026 01; 20(1):15-22.
    View in: PubMed
    Score: 0.441
  10. Shah VN, Dex T, Meneghini L, Rodrigues A, Polonsky WH. Treatment satisfaction and time in range after 16?weeks of treatment with iGlarLixi in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 05; 27(5):2523-2530.
    View in: PubMed
    Score: 0.436
  11. Karakus KE, Akturk HK, Snell-Bergeon JK, Shah VN. Progression of Diabetic Retinopathy After Initiation of Automated Insulin Delivery System in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2026 Jul; 20(4):1159-1163.
    View in: PubMed
    Score: 0.436
  12. Frías JP, Ratzki-Leewing A, Dex T, Meneghini L, Rodrigues A, Shah VN. Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes. Diabetes Obes Metab. 2025 04; 27(4):2173-2182.
    View in: PubMed
    Score: 0.435
  13. Shah VN, Agesen RM, Bardtrum L, Christiansen E, Snaith J, Greenfield JR. Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies. J Diabetes Sci Technol. 2025 03; 19(2):321-331.
    View in: PubMed
    Score: 0.431
  14. Shah VN, Peters AL, Umpierrez GE, Sherr JL, Akturk HK, Aleppo G, Bally L, Cengiz E, Cinar A, Dungan K, Fabris C, Jacobs PG, Lal RA, Mader JK, Masharani U, Prahalad P, Schmidt S, Zijlstra E, Ho CN, Ayers AT, Tian T, Aaron RE, Klonoff DC. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System. J Diabetes Sci Technol. 2025 01; 19(1):191-216.
    View in: PubMed
    Score: 0.428
  15. Klein MP, Akturk HK, Snell-Bergeon JK, Shah VN. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. 2025 03; 19(2):297-303.
    View in: PubMed
    Score: 0.411
  16. Shah VN, Al-Karadsheh A, Barnes C, Mandry J, Nakhle S, Wernicke-Panten K, Kramer D, Schmider W, Pierre S, Teichert L, Rotthaeuser B, Mukherjee B, Bailey TS. Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial. J Diabetes Sci Technol. 2025 07; 19(4):1051-1059.
    View in: PubMed
    Score: 0.408
  17. Shah VN, Akturk HK, Trahan A, Piquette N, Wheatcroft A, Schertz E, Carmello K, Mueller L, White K, Fu L, Sassan-Katchalski R, Messer LH, Habif S, Constantin A, Pinsker JE. Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ Technology. J Diabetes Sci Technol. 2024 11; 18(6):1281-1287.
    View in: PubMed
    Score: 0.406
  18. Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN. Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study. J Diabetes Sci Technol. 2025 03; 19(2):292-296.
    View in: PubMed
    Score: 0.406
  19. Shah VN, Akturk HK, Joseph H, Schneider N, Snell-Bergeon JK. A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec. Diabetes Obes Metab. 2021 08; 23(8):1936-1941.
    View in: PubMed
    Score: 0.339
  20. Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Miossec P, Mukherjee B, Shah VN. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial. Diabetes Technol Ther. 2020 07; 22(7):516-526.
    View in: PubMed
    Score: 0.311
  21. Shah VN, Forlenza GP. Suicide via Intentional Insulin Overdose Through First Commercial Hybrid Closed-Loop. J Diabetes Sci Technol. 2020 05; 14(3):687-688.
    View in: PubMed
    Score: 0.309
  22. Garg SK, Wernicke-Panten K, Wardecki M, Kramer D, Delalande F, Franek E, Sadeharju K, Monchamp T, Mukherjee B, Shah VN. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1). Diabetes Technol Ther. 2020 02; 22(2):85-95.
    View in: PubMed
    Score: 0.307
  23. Kaur H, Schneider N, Pyle L, Campbell K, Akturk HK, Shah VN. Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis. Diabetes Technol Ther. 2019 12; 21(12):736-739.
    View in: PubMed
    Score: 0.298
  24. Akturk HK, Shah VN. Severe Hypoglycemia in Adults With Type 1 Diabetes After Switching to Insulin Degludec. J Diabetes Sci Technol. 2018 05; 12(3):733-734.
    View in: PubMed
    Score: 0.264
  25. Garg SK, Giordano D, Gallo T, Shah VN. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2017 02; 19(S1):S128-S140.
    View in: PubMed
    Score: 0.250
  26. Shah VN, Shoskes A, Tawfik B, Garg SK. Closed-loop system in the management of diabetes: past, present, and future. Diabetes Technol Ther. 2014 Aug; 16(8):477-90.
    View in: PubMed
    Score: 0.210
  27. Garg SK, Michels AW, Shah VN. Use of non-insulin therapies for type 1 diabetes. Diabetes Technol Ther. 2013 Nov; 15(11):901-8.
    View in: PubMed
    Score: 0.199
  28. Shah VN, Moser EG, Blau A, Dhingra M, Garg SK. The future of basal insulin. Diabetes Technol Ther. 2013 Sep; 15(9):727-32.
    View in: PubMed
    Score: 0.196
  29. Riveline JP, Renard E, Aleppo G, Bode BW, Brown SA, Castorino K, Hirsch IB, Kipnes MS, Laffel LM, Lal RA, Penfornis A, Shah VN, Thivolet C, Weinstock RS. Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study. Diabetes Obes Metab. 2026 03; 28(3):2227-2236.
    View in: PubMed
    Score: 0.116
  30. Montaser E, Abad SE, Shah VN. Changes in A1C Versus GMI Across Glycemic Categories in Clinical Trials of Type 1 Diabetes. J Clin Endocrinol Metab. 2025 Nov 18; 110(12):e4182-e4187.
    View in: PubMed
    Score: 0.115
  31. Manjelievskaia J, Shah VN, Carlson AL, Isaacs D, Wang SM, Pinsker JE, Messer LH, McDermott KW, Lavelle K, Wall S, Brixner D, Malone DC, Stemple CA, Vaidya N, Patel BV. Retrospective analysis of impact of automated insulin delivery technology on acute care utilisation from 2019 to 2021. Diabet Med. 2025 Dec; 42(12):e70147.
    View in: PubMed
    Score: 0.114
  32. Turner LV, Sherr JL, Zaharieva DP, Baran J, Hirsch IB, Bode BW, Brown SA, Bzdick S, Church MM, Hansen DW, Kingman R, Laffel LM, Shah VN, Stone S, Vienneau TE, Huyett LM, Dumais B, Ly TT, Riddell MC. Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled Trial. Diabetes Care. 2025 Sep 01; 48(9):1598-1606.
    View in: PubMed
    Score: 0.113
  33. Zisser H, Hovorka R, Basu A, Battelino T, Boughton CK, Breton MD, Buckingham BA, Brown SA, Cherñavvsky DR, Dassau E, DeBoer MD, Doyle FJ, Ekhlaspour L, Fabris C, Forlenza GP, Haidar A, Klonoff DC, Kovatchev B, Kowalski AJ, Levy CJ, Kudva YC, Maahs DM, Phillip M, Renard E, Russell SJ, Shah VN, Steil GM, Wadwa RP, Weinzimer SA. Early Stages of Automated Insulin Delivery. J Diabetes Sci Technol. 2025 07; 19(4):908-923.
    View in: PubMed
    Score: 0.112
  34. Jacobs PG, Levy CJ, Brown SA, Riddell MC, Cinar A, Boughton CK, Breton MD, Dassau E, Forlenza G, Henderson RJ, Hovorka R, Maahs DM, Munshi M, Murphy H, Polsky S, Pratley R, Putman MS, Shah VN, Wilson LM, Zisser H, Ekhlaspour L. Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems. J Diabetes Sci Technol. 2025 07; 19(4):937-949.
    View in: PubMed
    Score: 0.112
  35. Zisser H, Hovorka R, Basu A, Battelino T, Boughton CK, Breton MD, Buckingham BA, Brown SA, Cherñavvsky DR, Dassau E, DeBoer MD, Doyle FJ, Ekhlaspour L, Fabris C, Forlenza GP, Haidar A, Klonoff DC, Kovatchev B, Kowalski AJ, Levy CJ, Kudva YC, Maahs DM, Phillip M, Renard E, Russell SJ, Shah VN, Steil GM, Wadwa RP, Weinzimer SA. Early Stages of Automated Insulin Delivery. Diabetes Technol Ther. 2025 07; 27(S3):S33-S47.
    View in: PubMed
    Score: 0.112
  36. Jacobs PG, Levy CJ, Brown SA, Riddell MC, Cinar A, Boughton CK, Breton MD, Dassau E, Forlenza G, Henderson RJ, Hovorka R, Maahs DM, Munshi M, Murphy H, Polsky S, Pratley R, Putman MS, Shah VN, Wilson LM, Zisser H, Ekhlaspour L. Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems. Diabetes Technol Ther. 2025 07; 27(S3):S60-S71.
    View in: PubMed
    Score: 0.112
  37. Pasquel FJ, Davis GM, Huffman DM, Peters AL, Parker JC, Laffel LM, Romeo GR, Mathew J, Castorino KN, Kruger DF, Dungan KM, Kipnes M, Jauch EC, Oser TK, Shah VN, Horowitz B, Carlson AL, Warren ML, Deeb W, Buse JB, Reed JH, Berner J, Blevins T, Bajaj C, Kollman C, Raghinaru D, Ly TT, Beck RW. Automated Insulin Delivery in Adults With Type 2 Diabetes: A Nonrandomized Clinical Trial. JAMA Netw Open. 2025 02 03; 8(2):e2459348.
    View in: PubMed
    Score: 0.109
  38. Brown SA, Laffel LM, Akturk HK, Forlenza GP, Shah VN, Wadwa RP, Cobry EC, Isganaitis E, Schoelwer M, Lu VS, Rueda R, Sherer N, Corbett JP, Sasson-Katchalski R, Pinsker JE. Randomized, Crossover Trial of Control-IQ Technology with a Lower Treatment Range and a Modified Meal Bolus Module in Adults, Adolescents, Children, and Preschoolers with Varying Levels of Baseline Glycemic Control. Diabetes Technol Ther. 2025 03; 27(3):187-193.
    View in: PubMed
    Score: 0.107
  39. Khare S, Zilbermint M, Garg R, Shah VN. Navigating the New Frontiers of Hyperglycemic Crisis Management: Unveiling the Latest American Diabetes Association Consensus Report. Endocr Pract. 2024 Sep; 30(9):895-897.
    View in: PubMed
    Score: 0.105
  40. Levy CJ, Bailey R, Laffel LM, Forlenza G, DiMeglio LA, Hughes MS, Brown SA, Aleppo G, Bhargava A, Shah VN, Clements MA, Kipnes M, Bruggeman B, Daniels M, Rodriguez H, Calhoun P, Lum JW, Sasson-Katchalski R, Pinsker JE, Pollom R, Beck RW. Multicenter Evaluation of Ultra-Rapid Lispro Insulin with Control-IQ Technology in Adults, Adolescents, and Children with Type 1 Diabetes. Diabetes Technol Ther. 2024 09; 26(9):652-660.
    View in: PubMed
    Score: 0.103
  41. Carlson AL, Graham TE, Akturk HK, Liljenquist DR, Bergenstal RM, Sulik B, Shah VN, Sulik M, Zhao P, Briggs P, Sassan-Katchalski R, Pinsker JE. Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial. J Diabetes Sci Technol. 2024 11; 18(6):1288-1292.
    View in: PubMed
    Score: 0.102
  42. Shah VN, Al-Karadsheh A, Barnes C, Mandry J, Nakhle S, Wernicke-Panten K, Kramer D, Schmider W, Pierre S, Teichert L, Rotthaeuser B, Mukherjee B, Bailey TS. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial. Diabetes Obes Metab. 2024 02; 26(2):540-547.
    View in: PubMed
    Score: 0.099
  43. Karakus KE, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade. Diabetes Care. 2023 09 01; 46(9):1646-1651.
    View in: PubMed
    Score: 0.098
  44. Shah VN. Limitations of Reporting Time Below Range as a Percentage. Diabetes Technol Ther. 2023 11; 25(11):822-825.
    View in: PubMed
    Score: 0.098
  45. Russell SJ, Beck RW, Damiano ER, El-Khatib FH, Ruedy KJ, Balliro CA, Li Z, Calhoun P, Wadwa RP, Buckingham B, Zhou K, Daniels M, Raskin P, White PC, Lynch J, Pettus J, Hirsch IB, Goland R, Buse JB, Kruger D, Mauras N, Muir A, McGill JB, Cogen F, Weissberg-Benchell J, Sherwood JS, Castellanos LE, Hillard MA, Tuffaha M, Putman MS, Sands MY, Forlenza G, Slover R, Messer LH, Cobry E, Shah VN, Polsky S, Lal R, Ekhlaspour L, Hughes MS, Basina M, Hatipoglu B, Olansky L, Bhangoo A, Forghani N, Kashmiri H, Sutton F, Choudhary A, Penn J, Jafri R, Rayas M, Escaname E, Kerr C, Favela-Prezas R, Boeder S, Trikudanathan S, Williams KM, Leibel N, Kirkman MS, Bergamo K, Klein KR, Dostou JM, Machineni S, Young LA, Diner JC, Bhan A, Jones JK, Benson M, Bird K, Englert K, Permuy J, Cossen K, Felner E, Salam M, Silverstein JM, Adamson S, Cedeno A, Meighan S, Dauber A. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022 09 29; 387(13):1161-1172.
    View in: PubMed
    Score: 0.092
  46. Akturk HK, Snell-Bergeon J, Shah VN. Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes. Diabetes Technol Ther. 2022 10; 24(10):779-783.
    View in: PubMed
    Score: 0.091
  47. Champakanath A, Akturk HK, Alonso GT, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Diabetes Care. 2022 03 01; 45(3):750-753.
    View in: PubMed
    Score: 0.089
  48. Garg SK, Rodriguez E, Shah VN, Hirsch IB. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2022 03; 24(S1):S190-S208.
    View in: PubMed
    Score: 0.089
  49. Jackson MA, Ahmann A, Shah VN. Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring. Diabetes Technol Ther. 2021 03; 23(S1):S27-S34.
    View in: PubMed
    Score: 0.083
  50. Shah VN. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med. 2021 02 25; 384(8):e26.
    View in: PubMed
    Score: 0.083
  51. Shah VN, Garg SK. Standardized Hybrid Closed-Loop System Reporting. Diabetes Technol Ther. 2021 05; 23(5):323-331.
    View in: PubMed
    Score: 0.081
  52. Akturk HK, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes. Diabetes Technol Ther. 2021 01; 23(1):81-83.
    View in: PubMed
    Score: 0.079
  53. Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes. Diabetes Technol Ther. 2019 01; 21(1):6-10.
    View in: PubMed
    Score: 0.071
  54. Tauschmann M, Thabit H, Bally L, Allen JM, Hartnell S, Wilinska ME, Ruan Y, Sibayan J, Kollman C, Cheng P, Beck RW, Acerini CL, Evans ML, Dunger DB, Elleri D, Campbell F, Bergenstal RM, Criego A, Shah VN, Leelarathna L, Hovorka R. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018 10 13; 392(10155):1321-1329.
    View in: PubMed
    Score: 0.070
  55. Polsky S, Wu M, Bode BW, DuBose SN, Goland RS, Maahs DM, Foster NC, Peters AL, Levy CJ, Shah VN, Beck RW. Diabetes Technology Use Among Pregnant and Nonpregnant Women with T1D in the T1D Exchange. Diabetes Technol Ther. 2018 08; 20(8):517-523.
    View in: PubMed
    Score: 0.069
  56. Haymond MW, DuBose SN, Rickels MR, Wolpert H, Shah VN, Sherr JL, Weinstock RS, Agarwal S, Verdejo AS, Cummins MJ, Newswanger B, Beck RW. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes. J Clin Endocrinol Metab. 2017 08 01; 102(8):2994-3001.
    View in: PubMed
    Score: 0.065
  57. Bally L, Thabit H, Tauschmann M, Allen JM, Hartnell S, Wilinska ME, Exall J, Huegel V, Sibayan J, Borgman S, Cheng P, Blackburn M, Lawton J, Elleri D, Leelarathna L, Acerini CL, Campbell F, Shah VN, Criego A, Evans ML, Dunger DB, Kollman C, Bergenstal RM, Hovorka R. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol. BMJ Open. 2017 Jul 13; 7(7):e016738.
    View in: PubMed
    Score: 0.064
  58. Renard E, Weinstock RS, Aleppo G, Bode BW, Brown SA, Castorino K, Hirsch IB, Kipnes MS, Laffel LM, Lal RA, Penfornis A, Riveline JP, Shah VN, Thivolet C, Ly TT. Efficacy and Safety of a Tubeless AID System Compared With Pump Therapy With CGM in the Treatment of Type 1 Diabetes in Adults With Suboptimal Glycemia: A Randomized, Parallel-Group Clinical Trial. Diabetes Care. 2024 12 01; 47(12):2248-2257.
    View in: PubMed
    Score: 0.027
  59. Brett McQueen R, Perez-Nieves M, Todd Alonso G, Fan L, Hankosky ER, Shah VN, Yan Y, Ellis SL, Juneja R. Association between continuous glucose monitoring metrics and clinical outcomes in adults with type 1 diabetes in a real-world setting. Diabetes Res Clin Pract. 2024 Jun; 212:111690.
    View in: PubMed
    Score: 0.026
  60. Criego AB, Carlson AL, Brown SA, Forlenza GP, Bode BW, Levy CJ, Hansen DW, Hirsch IB, Bergenstal RM, Sherr JL, Mehta SN, Laffel LM, Shah VN, Bhargava A, Weinstock RS, MacLeish SA, DeSalvo DJ, Jones TC, Aleppo G, Buckingham BA, Ly TT. Two Years with a Tubeless Automated Insulin Delivery System: A Single-Arm Multicenter Trial in Children, Adolescents, and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2024 01; 26(1):11-23.
    View in: PubMed
    Score: 0.025
  61. Karakus KE, Shah VN, Klonoff D, Akturk HK. Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes. Diabetes Obes Metab. 2023 11; 25(11):3144-3151.
    View in: PubMed
    Score: 0.024
  62. Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O'Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocr Rev. 2023 03 04; 44(2):254-280.
    View in: PubMed
    Score: 0.024
  63. Polonsky WH, Hood KK, Levy CJ, MacLeish SA, Hirsch IB, Brown SA, Bode BW, Carlson AL, Shah VN, Weinstock RS, Bhargava A, Jones TC, Aleppo G, Mehta SN, Laffel LM, Forlenza GP, Sherr JL, Huyett LM, Vienneau TE, Ly TT. How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod® 5 System. Diabetes Res Clin Pract. 2022 Aug; 190:109998.
    View in: PubMed
    Score: 0.023
  64. Miller KM, Kanapka LG, Rickels MR, Ahmann AJ, Aleppo G, Ang L, Bhargava A, Bode BW, Carlson A, Chaytor NS, Gannon G, Goland R, Hirsch IB, Kiblinger L, Kruger D, Kudva YC, Levy CJ, McGill JB, O'Malley G, Peters AL, Philipson LH, Philis-Tsimikas A, Pop-Busui R, Salam M, Shah VN, Thompson MJ, Vendrame F, Verdejo A, Weinstock RS, Young L, Pratley R. Benefit of Continuous Glucose Monitoring in Reducing Hypoglycemia Is Sustained Through 12 Months of Use Among Older Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 06; 24(6):424-434.
    View in: PubMed
    Score: 0.022
  65. Hughes MS, Bailey R, Calhoun P, Shah VN, Lyons SK, DeSalvo DJ. Off-label use of sodium glucose co-transporter inhibitors among adults in type 1 diabetes exchange registry. Diabetes Obes Metab. 2022 01; 24(1):171-173.
    View in: PubMed
    Score: 0.022
  66. Brown SA, Forlenza GP, Bode BW, Pinsker JE, Levy CJ, Criego AB, Hansen DW, Hirsch IB, Carlson AL, Bergenstal RM, Sherr JL, Mehta SN, Laffel LM, Shah VN, Bhargava A, Weinstock RS, MacLeish SA, DeSalvo DJ, Jones TC, Aleppo G, Buckingham BA, Ly TT. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care. 2021 07; 44(7):1630-1640.
    View in: PubMed
    Score: 0.021
  67. Pratley RE, Kanapka LG, Rickels MR, Ahmann A, Aleppo G, Beck R, Bhargava A, Bode BW, Carlson A, Chaytor NS, Fox DS, Goland R, Hirsch IB, Kruger D, Kudva YC, Levy C, McGill JB, Peters A, Philipson L, Philis-Tsimikas A, Pop-Busui R, Shah VN, Thompson M, Vendrame F, Verdejo A, Weinstock RS, Young L, Miller KM. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020 06 16; 323(23):2397-2406.
    View in: PubMed
    Score: 0.020
  68. Carlson AL, Kanapka LG, Miller KM, Ahmann AJ, Chaytor NS, Fox S, Kiblinger L, Kruger D, Levy CJ, Peters AL, Rickels MR, Salam M, Shah VN, Young LA, Kudva YC, Pratley R. Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM Study. J Diabetes Sci Technol. 2021 05; 15(3):582-592.
    View in: PubMed
    Score: 0.019
  69. Dovc K, Boughton C, Tauschmann M, Thabit H, Bally L, Allen JM, Acerini CL, Arnolds S, de Beaufort C, Bergenstal RM, Campbell F, Criego A, Dunger DB, Elleri D, Evans ML, Fröhlich-Reiterer E, Hofer S, Kapellen T, Leelarathna L, Pieber TR, Rami-Merhar B, Shah VN, Sibayan J, Wilinska ME, Hovorka R. Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery. Diabetes Care. 2019 07; 42(7):1344-1347.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)